Testing one drug, alone or with a second drug, for HER2-low breast cancer that has spread to the brain
Original title: T-DXd With or Without Bevacizumab for HER2-low Breast Cancer With Brain Metastasis
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a middle stage trial that is still testing how well the drugs work.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This trial tests a cancer drug, by itself or paired with another drug, in people whose breast cancer has spread to the brain.
Who this trial is for. This trial is for people with HER2-low breast cancer that has spread to the brain. It tests a drug called trastuzumab deruxtecan, given alone or together with a drug called bevacizumab: A drug that acts on the blood vessels a tumor builds. In brain tumors it is used mainly to control symptoms from swelling, and to reduce how much steroid someone needs. See the glossary.
Where it stands. The trial has not reported results. It is looking at how well these drugs work and how safe they are. The answer is not in yet.
What this means, and what it doesn't
What it could mean: Nothing is proven here yet. If this sounds like your situation, you could ask your care team about it. They can help you decide if a trial like this is worth looking into.
What it doesn't mean: This does not mean the drugs work. A trial is a test, not a proven treatment. Being in one is not a guarantee that you will be helped. It is not a promise of a cure.
Source: ClinicalTrials.gov, September 25, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.